Acticor Biotech is a technology company.
Acticor Biotech is a technology company.
Acticor Biotech has raised $30.0M across 4 funding rounds.
Acticor Biotech has raised $30.0M in total across 4 funding rounds.
Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, a first-in-class humanized monoclonal antibody fragment targeting platelet glycoprotein GPVI to treat thrombotic diseases, primarily acute ischemic stroke. It serves patients with cardiovascular emergencies, addressing the unmet need for effective antithrombotic therapy that inhibits pathological platelet aggregation without increasing bleeding risks, unlike existing treatments.[1][2][3][4] The company has advanced glenzocimab through key trials: positive Phase 1b/2a ACTIMIS results in 2022 confirming safety as an add-on to standard care, and completion of the international Phase 2/3 adaptive ACTISAVE trial in January 2024 with 436 patients, results presented in May 2024.[1][4]
Founded in November 2013 as a spin-off from INSERM (French National Institute of Health and Medical Research), Acticor Biotech emerged from research by its founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Professor Philippe Billiald at Paris-Sud University.[1][2][4] Headquartered in Paris, France, the company built on their expertise in platelet biology to target GPVI for safer antithrombotics. Early milestones include the Phase 1b/2a ACTIMIS trial (NCT03803007) launched pre-2022 with positive safety data announced February 2022, and the ACTISAVE Phase 2/3 trial (NCT05070260) started in September 2021.[1][2] It went public on Euronext Growth in November 2021 via IPO.[5]
Acticor Biotech rides the wave of precision biopharma targeting unmet needs in cardiovascular emergencies, where ischemic stroke—60-80% of strokes—drives high morbidity/mortality despite thrombolysis limitations like bleeding risks.[1][2] Timing aligns with advances in monoclonal antibodies and adaptive trial designs (e.g., ACTISAVE's efficiency), amid rising stroke incidence from aging populations and post-COVID vascular insights.[2][4] Market forces favor it: growing demand for safer antithrombotics in a $20B+ stroke market, plus Euronext listing enabling funding for late-stage trials. It influences the ecosystem by validating GPVI as a therapeutic target, potentially inspiring spin-offs and collaborations in thrombotic biotech.[1][3][5]
Acticor Biotech's path hinges on ACTISAVE data analysis post-May 2024 presentation, potentially unlocking Phase 3 efficacy trials, regulatory filings, or partnerships for commercialization in stroke and beyond.[1][4] Trends like AI-optimized trials, combo therapies with thrombectomy, and global stroke burden (e.g., China's scale) will shape its trajectory, with GPVI inhibitors gaining traction if bleeding safety holds.[2] Its influence may evolve from clinical pioneer to market leader if glenzocimab proves superior, transforming acute stroke care from reactive to targeted—echoing its INSERM roots in innovative thrombotic solutions.[1][3]
Acticor Biotech has raised $30.0M in total across 4 funding rounds.
Acticor Biotech's investors include Go Capital, Karista.
Acticor Biotech has raised $30.0M across 4 funding rounds. Most recently, it raised $8.0M Series B in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $8.0M Series B | Go Capital, Karista | |
| Oct 1, 2018 | $18.0M Series B | Karista | |
| Jan 1, 2018 | $2.0M Series A | Karista | |
| Feb 1, 2017 | $2.0M Venture Round | Karista |